127O - Programmed cell death 1 ligand 1 expression and association with survival in mesothelioma

Date 27 March 2014
Event ELCC 2014
Session Proffered Papers 2 - Tumour biology and translational research
Topics Mesothelioma
Translational Research
Presenter Aaron Mansfield
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors A.S. Mansfield1, T. Peikert2, A. Roden3, C. Krco4, S. Harrington5, H. Dong5, E. Kwon5
  • 1Medical Oncology, Mayo Clinic, 55905 - Rochester/US
  • 2Pulmonology, Mayo Clinic, Rochester/US
  • 3Laboratory Medicine And Pathology, Mayo Clinic, Rochester/US
  • 4Immunology, Mayo Clinic, Rochester/US
  • 5Urology, Mayo Clinic, Rochester/US



Due to the role Programmed Cell Death 1 Ligand 1 (PD-L1, aka B7-H1) has in establishing immune tolerance, its associations with worse survival in patients with many human malignancies, and the availability of agents to target PD-1:PD-L1 interactions, we decided to investigate the expression of PD-L1 in mesothelioma with the goal of exploring whether it might serve as a therapeutic target.